By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Regeneron Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-847-7000 Fax: n/a


SEARCH JOBS



Known for its scientific and operational excellence, Regeneron is a leading science-based biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

Visit our website – www.regeneron.com
Check out our openings – http://careers.regeneron.com


Key Statistics


Email:
Ownership: Public

Web Site: Regeneron
Employees: 2300+
Symbol: REGN
 





Collaborations

Sanofi US 

Bayer 

Geisinger Health System  Collaboration with Regeneron Genetics Center LLC, wholly-owned subsidiary of Regeneron.

Avalanche Biotech 





Company News
Regeneron (REGN) CEO Says Amgen (AMGN) Not Putting Patients First In Patent Dispute 1/10/2017 6:58:53 AM
Regeneron (REGN) Hires Jay Markowitz, M.D., As Senior Vice President Of Portfolio 1/4/2017 8:05:41 AM
Sanofi (SNY), Regeneron (REGN) Lose Bid To Overturn Amgen (AMGN) Win In Patent Case 1/4/2017 7:02:43 AM
A Turnaround: Regeneron (REGN) Eyes a Comeback in 2017 12/28/2016 7:51:48 AM
Regeneron (REGN) Release: Science Publication Highlights The Precision Medicine Approach Of The Regeneron Genetics Center And Geisinger Health System 12/27/2016 9:33:36 AM
Booming Regeneron (REGN) Buys Another Building in New York 12/15/2016 7:07:05 AM
Regeneron (REGN) And Sanofi (SNY)i Announce Marketing Authorization Application For Dupixent (Dupilumab) Accepted For Review By The EMA 12/8/2016 8:10:29 AM
No Early Success for Regeneron (REGN) and Sanofi (SNY)'s Cholesterol Drug Praluent 11/17/2016 5:52:03 AM
Regeneron (REGN) And Sanofi (SNY) Present Results From Phase 3 MONARCH Study Of Investigational Sarilumab At American College of Rheumatology Annual Meeting 11/16/2016 7:50:55 AM
Regeneron (REGN) And Sanofi (SNY) To Present Data From Phase 3 Praluent (Alirocumab) Injection Clinical Trials At AHA Scientific Sessions 2016 11/11/2016 11:14:17 AM
12345678910...
//-->